Post transplant lymphoproliferative disorders (PTLDs) occur in 0.7-32% of solid organ transplant (SOT) patients.
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Most PTLDs are derived from B-lineage lymphocytes and are associated with active Epstein-Barr virus (EBV) infection. 1, 2 As these disorders are aggressive, the prognosis for patients with PTLDs is poor, and 50-80% of patients who have monoclonal PTLDs after undergoing SOTs die. 1 In fact, PTLDs are the main cause of morbidity and mortality among high-risk transplant recipients. 2 Among the factors predictive of survival in patients with PTLDs are performance status and the number of involved sites. 3 The occurrence of PTLD depends on the type, degree, and duration of the immunosuppressive therapy administered. The restoration of immunocompetence is the first-line treatment for PTLDs, but many patients also require: surgery, radiotherapy, chemotherapy, or immunotherapy. 4 The following case study describes a patient diagnosed with diffuse large B-cell lymphoma (DLBCL) 14 years after a liver transplant who was successfully treated with chemotherapy, monoclonal antibodies, and autologous stem cell transplantation (ASCT).
The patient, Caucasian woman, at the age of 35 years received an orthotopic liver transplant for biliary cirrhosis and remained asymptomatic with cyclosporine alone. After 14 years, the patient was admitted to our hospital with malaise, fever, and abdominal pain. Computed tomography and laparotomy revealed an abdominal mass about 9 cm in diameter involving the small bowel. Histological study revealed DLBCL (CD20 positive). The tumor cells were negative for EBV (latent membrane protein 1 was negative by immunohistochemical analysis). BCL-2 was negative by immunohistochemical analysis. The patient's clinical characteristics comprised the following: Ann Arbor stage IV disease, performance status 2, normal lactate dehydrogenase, and the involvement of more than two extranodal sites (intestine, bone marrow, and central nervous system (CNS)). Involvement of the CNS was confirmed by the presence of tumor cells in the cerebrospinal fluid and was associated with meningeal symptoms. Cyclosporine was stopped, and the patient was given eight cycles of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), anti-CD20 antibody (rituximab), and 10 intrathecal therapies (methotrexate, cytarabine, and hydrocortisone). Rituximab was administered with each chemotherapy cycle on day 1. The patient's disease went into complete remission but because of her poor prognosis (low performance status and disseminated disease), we decided to administer intensification treatment with ASCT. The conditioning regimen comprised carmustine, etoposide, cytarabine, and melphalan (BEAM), and the source of hematopoietic stem cells was the peripheral blood. She suffered no significant complications and soon recovered adequate neutrophil (day 15 after progenitor cell infusion) and platelet (day 16 after progenitor cell infusion) levels. Her liver function remained normal, and hepatic rejection did not occur. At 18 months after ASCT, the patient's disease remains in complete remission and she has started tacrolimus (FK506) treatment.
In general, the time elapsed between transplantation and the onset of PTLDs allows one to identify which of the two groups, with different disease features and potentially different pathogenesis, a patient belongs to. 5 Early-onset PTLDs represent more than 80% of all PTLDs and are usually caused by EBV infection. The histological and molecular patterns are frequently polyclonal, and the clinical presentation is very heterogeneous, involving nodal or extranodal disease. 1 Restoring immunocompetence is the first-line treatment, and it determines whether complete regression will occur in most early PTLDs. Late occurring PTLDs have different characteristics: they are usually monoclonal proliferations and the EBV genome is frequently absent. 4 The clinical presentation is quite similar to that of lymphomas in nonimmunocompromised patients. The treatment of late PTLDs remains controversial, however. Immunosuppression discontinuation is usually required, as are additional treatments such as surgery, radiotherapy, chemotherapy, and recently immunotherapy (with interferon or rituximab). 4 Rituximab can be effective for the management of B-cell post transplant lymphoproliferative disorders. 4, 6 Chemotherapy administered with rituximab has been shown to be a good approach for patients with diffuse aggressive lymphomas that occur long after SOT. Although it is highly toxic, chemotherapy seems to be more successful in patients with disseminated disease who did not respond to reduce immunosuppression.
The role of ASCT in the treatment of PTLDs is currently unclear. Owing to the poor prognosis of late PTLDs, ASCT may be a rational treatment option. Experience with bone marrow transplantation after SOT is limited, however. The role of autologous stem cell transplant in patients with DLBCL in first CR -regardless of IPI -is still unproven. We found only 11 cases reported in the literature [7] [8] [9] [10] and only two cases of autologous transplantation 7, 10 (see Table 1 ). One of these, reported by Lohrisch et al, 
